Sort   by:  
 Page size 
UnknownA dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Not available
S-EPMC10289989 | biostudies-literature
UnknownUS expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan.
Not available
S-EPMC12325563 | biostudies-literature
UnknownOral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.
Not available
S-EPMC4971919 | biostudies-literature
UnknownRibociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
Not available
S-EPMC5847028 | biostudies-literature
UnknownEfficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
Not available
S-EPMC9357270 | biostudies-literature
UnknownA single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
Not available
S-EPMC4705837 | biostudies-literature
UnknownTumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types.
Not available
S-EPMC11815411 | biostudies-literature
UnknownPhase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Not available
S-EPMC4682258 | biostudies-literature
Unknownnab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Not available
S-EPMC6096741 | biostudies-literature
UnknownA phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors.
Not available
S-EPMC12722991 | biostudies-literature
Sort   by:  
 Page size